Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Integration of functional immunomonitoring assays with PET/CT scans in TB patients identifies on-treatment biomarkers.

bioRxiv : the preprint server for biology·2026

Same author

Synthesis of 4-Aminoindole-Containing Cephalosporin Prodrugs and Their Biological Activity against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026

Same author

<i>In vitro</i> dormancy models improve ability to predict treatment response in severe marmoset tuberculosis lesions.

bioRxiv : the preprint server for biology·2026

Same author

Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026

Same author

PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort study.

The Lancet. Respiratory medicine·2026

Same author

Optimisation and application of a T-cell antigen-specific activation assay as diagnostic and treatment-monitoring tool for tuberculosis.

ERJ open research·2026

Search research articles

Related Experiment Video

Updated: Apr 3, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Tuberculosis.

Keertan Dheda¹, Clifton E Barry², Gary Maartens³

¹Lung Infection and Immunity Unit, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa; Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.

Lancet (London, England)

|September 18, 2015

Summary

This summary is machine-generated.

Tuberculosis remains a global health threat, with rising drug resistance and incidence in Africa. New drugs and diagnostics offer hope, but eradication requires addressing poverty, HIV, and other co-factors.

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

Related Experiment Videos

Last Updated: Apr 3, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

Area of Science:

Public Health
Infectious Diseases
Global Health

Background:

Tuberculosis (TB) incidence is decreasing globally but remains substantial, causing millions of deaths annually.
Rising drug resistance and incidence in regions like Africa, coupled with HIV prevalence, poverty, and drug-resistant TB strains, threaten progress.
Tuberculosis poses a significant risk to healthcare workers globally.

Purpose of the Study:

To review the current global tuberculosis landscape, including challenges and recent advancements.
To highlight the impact of co-existing conditions and socioeconomic factors on tuberculosis control.
To discuss the future prospects for tuberculosis prevention and eradication.

Main Methods:

Review of global tuberculosis statistics and trends.
Analysis of factors influencing tuberculosis incidence and drug resistance.
Assessment of recent developments in tuberculosis diagnostics and therapeutics.

Main Results:

Despite a slow global decrease in incidence, tuberculosis remains a major cause of mortality.
Emerging drug resistance and co-infections like HIV are significant challenges.
New diagnostic tools and two new drugs offer improved treatment options after a long gap.

Conclusions:

While new interventions and investments are crucial for tuberculosis control, eradication necessitates addressing poverty, overcrowding, and co-drivers like HIV, smoking, and diabetes.
Achieving herd immunity through vaccination remains a long-term goal due to incomplete understanding of protective immunity.
Political will and stability are essential for sustained tuberculosis control and eventual eradication.